Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized controlled trial
Background: The global attention to the capacities of traditional medicine for alleviating the clinical manifestations of COVID-19 has been growing. The present trial aimed to evaluate the efficacy and safety of a Persian herbal medicine formula among patients with COVID-19. Methods: The present tri...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Integrative Medicine Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213422022000373 |
| _version_ | 1828154178058321920 |
|---|---|
| author | Mohammad Setayesh Mehrdad Karimi Arman Zargaran Hamid Abousaidi Armita Shahesmaeili Fatemeh Amiri Fatemeh Sadat Hasheminasab |
| author_facet | Mohammad Setayesh Mehrdad Karimi Arman Zargaran Hamid Abousaidi Armita Shahesmaeili Fatemeh Amiri Fatemeh Sadat Hasheminasab |
| author_sort | Mohammad Setayesh |
| collection | DOAJ |
| description | Background: The global attention to the capacities of traditional medicine for alleviating the clinical manifestations of COVID-19 has been growing. The present trial aimed to evaluate the efficacy and safety of a Persian herbal medicine formula among patients with COVID-19. Methods: The present trial was conducted in Afzalipour hospital, Kerman, Iran, from June to September 2020. Hospitalized COVID-19 patients were randomly divided into intervention (Persian herbal medicine formula + routine treatment) or control (only routine treatment) groups. The intervention group received both capsule number 1 and 2 every 8 hours for 7 days. Capsule number 1 contained extract of the Glycyrrhiza glabra, Punica granatum, and Rheum palmatum, and the second capsule was filled by Nigella sativa powder. Participants were followed up to 7 days. The primary outcome was the number of hospitalization days, while cough, fever, and respiratory rate, days on oxygen (O2) therapy, and mortality rate were considered as the secondary outcomes. Results: Eighty-two patients were enrolled to the study, while 79 cases completed the trial and their data were analyzed (mean age: 59.1 ± 17.1 years). Based on the results, the Persian medicine formula decreased the mean hospitalization days, so that the mean difference of length of hospitalization as primary outcome was 2.95 ± 0.43 days. A significant clinical improvement was observed regarding dyspnea, need for O2) therapy, and respiratory rate in the intervention group. No adverse effects were reported. Conclusion: The present study supported the use of the Persian medicine formula as an adjuvant therapy for hospitalized COVID-19 patients. Study registration: Iranian Registry of Clinical Trials (www.irct.ir): IRCT20200330046899N1. |
| first_indexed | 2024-04-11T22:36:25Z |
| format | Article |
| id | doaj.art-25e52ec132ed4a6daba3c89eb31b54f3 |
| institution | Directory Open Access Journal |
| issn | 2213-4220 |
| language | English |
| last_indexed | 2024-04-11T22:36:25Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Integrative Medicine Research |
| spelling | doaj.art-25e52ec132ed4a6daba3c89eb31b54f32022-12-22T03:59:12ZengElsevierIntegrative Medicine Research2213-42202022-09-01113100869Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized controlled trialMohammad Setayesh0Mehrdad Karimi1Arman Zargaran2Hamid Abousaidi3Armita Shahesmaeili4Fatemeh Amiri5Fatemeh Sadat Hasheminasab6Department of Traditional Medicine, School of Persian medicine, Kerman University of Medical Sciences, Kerman, IranDepartment of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, IranResearch Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, IranHIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health Kerman University of Medical Sciences, Kerman, IranAfzalipour Hospital, Kerman University of Medical Sciences, Kerman, IranPharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran; Corresponding author at: Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.Background: The global attention to the capacities of traditional medicine for alleviating the clinical manifestations of COVID-19 has been growing. The present trial aimed to evaluate the efficacy and safety of a Persian herbal medicine formula among patients with COVID-19. Methods: The present trial was conducted in Afzalipour hospital, Kerman, Iran, from June to September 2020. Hospitalized COVID-19 patients were randomly divided into intervention (Persian herbal medicine formula + routine treatment) or control (only routine treatment) groups. The intervention group received both capsule number 1 and 2 every 8 hours for 7 days. Capsule number 1 contained extract of the Glycyrrhiza glabra, Punica granatum, and Rheum palmatum, and the second capsule was filled by Nigella sativa powder. Participants were followed up to 7 days. The primary outcome was the number of hospitalization days, while cough, fever, and respiratory rate, days on oxygen (O2) therapy, and mortality rate were considered as the secondary outcomes. Results: Eighty-two patients were enrolled to the study, while 79 cases completed the trial and their data were analyzed (mean age: 59.1 ± 17.1 years). Based on the results, the Persian medicine formula decreased the mean hospitalization days, so that the mean difference of length of hospitalization as primary outcome was 2.95 ± 0.43 days. A significant clinical improvement was observed regarding dyspnea, need for O2) therapy, and respiratory rate in the intervention group. No adverse effects were reported. Conclusion: The present study supported the use of the Persian medicine formula as an adjuvant therapy for hospitalized COVID-19 patients. Study registration: Iranian Registry of Clinical Trials (www.irct.ir): IRCT20200330046899N1.http://www.sciencedirect.com/science/article/pii/S2213422022000373Glycyrrhiza glabraNigella sativaRheum palmatumCOVID-19Persian medicineherbal medicine |
| spellingShingle | Mohammad Setayesh Mehrdad Karimi Arman Zargaran Hamid Abousaidi Armita Shahesmaeili Fatemeh Amiri Fatemeh Sadat Hasheminasab Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized controlled trial Integrative Medicine Research Glycyrrhiza glabra Nigella sativa Rheum palmatum COVID-19 Persian medicine herbal medicine |
| title | Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized controlled trial |
| title_full | Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized controlled trial |
| title_fullStr | Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized controlled trial |
| title_full_unstemmed | Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized controlled trial |
| title_short | Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized controlled trial |
| title_sort | efficacy of a persian herbal medicine compound on coronavirus disease 2019 covid 19 a randomized controlled trial |
| topic | Glycyrrhiza glabra Nigella sativa Rheum palmatum COVID-19 Persian medicine herbal medicine |
| url | http://www.sciencedirect.com/science/article/pii/S2213422022000373 |
| work_keys_str_mv | AT mohammadsetayesh efficacyofapersianherbalmedicinecompoundoncoronavirusdisease2019covid19arandomizedcontrolledtrial AT mehrdadkarimi efficacyofapersianherbalmedicinecompoundoncoronavirusdisease2019covid19arandomizedcontrolledtrial AT armanzargaran efficacyofapersianherbalmedicinecompoundoncoronavirusdisease2019covid19arandomizedcontrolledtrial AT hamidabousaidi efficacyofapersianherbalmedicinecompoundoncoronavirusdisease2019covid19arandomizedcontrolledtrial AT armitashahesmaeili efficacyofapersianherbalmedicinecompoundoncoronavirusdisease2019covid19arandomizedcontrolledtrial AT fatemehamiri efficacyofapersianherbalmedicinecompoundoncoronavirusdisease2019covid19arandomizedcontrolledtrial AT fatemehsadathasheminasab efficacyofapersianherbalmedicinecompoundoncoronavirusdisease2019covid19arandomizedcontrolledtrial |